| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 93.0 | 78.2 | 65.6 |
| Other income | 3.2 | 1.9 | 1.7 |
| Total income | 96.2 | 80.1 | 67.4 |
| Profit before exceptional items & tax | 3.1 | 2.6 | 3.8 |
| Exceptional items | 0.0 | 0.2 | 0.2 |
| Profit before tax | 3.1 | 2.3 | 3.5 |
| Net profit | 1.6 | 2.3 | 1.4 |
| Operating margin | 3.2% | 2.9% | 5.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +14.30% |
|---|---|
| Net profit, quarter on quarter | -30.40% |
| Revenue, year on year | +41.80% |
Source
Read the filing ↗
NSE results filing, NSE: ZENITHDRUG. Figures extracted from the filing.
Zenith Drugs Ltd: key numbers
- Share price
- ₹42.80
- Market cap
- ₹73.40 Cr
- Revenue (annual)
- ₹171.2 Cr
- Net profit (annual)
- ₹3.94 Cr
- P/E (TTM)
- 18.6×Sector 50.4×
- Promoter holding
- 69.98%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zenith Drugs Ltd
All →
13:13 IST
NSE
Annual General Meeting
Zenith Drugs Annual General Meeting
Zenith Drugs Limited has issued a notice for its 26th Annual General Meeting scheduled for September 29, 2026, to transact various ordinary and special business.
13:07 IST
NSE
Board Meeting Outcome
Zenith Drugs Board Meeting Outcome
Zenith Drugs Limited announced the notice for its 26th AGM and appointed a secretarial auditor and a scrutinizer for the meeting.